Abstract:Protein conformational change and amyloid fibrils deposition are associated with severe diseases.Those proteins include amyloid-β protein (Aβ,Alzheimer's disease),human islet amyloid polypeptide (hIAPP,type 2 diabetes mellitus,T2DM),and prion protein (PrP,transmissible spongiform encephalopathies).Scientists have focused on studying these amyloid proteins to develop potential drugs against the diseases.Prion disease is a type of chronic progressive fatal neurodegenerative disease,whose pathogenic mechanism is the conformational conversion of normal prion protein PrPc to a pathogenic type PrPSc.The transition produces amyloid deposition and consequent neurotoxicity.PrP115-135 (115-AAAAGAVVGGLGGYMLGSAMS-135) is an N-terminal fragment of PrP with self-aggregation and cytotoxicity.Metal complexes act as traditional antitumor agents,and non-platinum-based metallodrugs are developed to improve clinical effectiveness in terms of their general toxicity and spectral activity.Besides,they interact with various proteins,enzymes and bioactive peptides.Ruthenium complexes can effectively bind to proteins,such as apotransferrin,apolactoferrin,and serum albumin,resulting in the altered protein structure and binding ability toward other molecules.They are also considered as potential inhibitors of amyloid proteins because of their low cytotoxicity and disaggregation ability to amyloid fibrils.This work studied the interactions of PrP115-135 with two ruthenium complexes NAMI-A and KP418 in order to compare the action mechanisms between different prion neuropeptides and ruthenium complexes.The intrinsic fluorescence method and cyclic voltammetry (CV) were used to study the binding mode and binding affinity of the two complexes to PrP15-135.In addition,we used Thioflavin T fluorescence assay to display the effects of ruthenium complexes on amyloid peptide aggregation.Furthermore,3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to reveal the effects of ruthenium complexes on amyloid peptide-induced cytotoxicity.The change in peptide fluorescence upon metal complex addition could be assumed to reflect the amounts of peptide-ruthenium complex produced and the conformational change of the peptide.The dissociation constant Kd values were (6.2±1.4) and (6.4±1.1) μmol/L for KP418 and NAMI-A respectively,indicating a strong binding affinity between the peptide and ruthenium complexes.CV method showed that,the reduction potential of the complexes changed with the addition of the peptide,reducing the peak current as well.The change of reduction potential indicated that the interaction between them was attributed to electrostatic interaction,and the decrease of the reduction peak current implied that there were other binding forces,such as hydrophobic interaction existed.ThT assay showed that,after incubating ruthenium complexes with aggregated PrP115-135,the fluorescence intensity decreased dramatically.It suggested that the two complexes effectively inhibited the aggregation of peptide.The aggregation kinetics indicated that the complex could significantly prolong the nucleation period and aggregation time of amyloid peptide.Ruthenium complexes could bind to PrP115-135 and inhibit their aggregation,forming oligomers or monomers,thereby reducing the cytotoxicity of PrP115-135 and improving the survival rate of cells.The inhibitory effect of the two complexes on the aggregation of PrP115-135,and their rescue of peptide induced cytotoxicity make it possible for them to be inhibitors of peptide aggregation and potential drugs against amyloidosis.Exploring metal complexes with low toxicity,better disaggregation ability and good water solubility that can penetrate the blood-brain barrier is a principal research direction in this field.So our next step will keep on configuration design of the complexes so as to find potential metallodrugs against prion disease.

Modulation of aggregation of human prion protein PrP106-126 by indole-based cyclometallated palladium complex

Palladium Complexes Affect the Aggregation of Human Prion Protein PrP106-126.

Regulation of Aggregation Behavior and Neurotoxicity of Prion Neuropeptides by Platinum Complexes.

Inhibitory Effects of NAMI-A-like Ruthenium Complexes on Prion Neuropeptide Fibril Formation.

Effect of cycloastragenol and punicalagin on Prp(106-126) and Aβ(25-35) oligomerization and fibrillizaton

Inhibition of human prion neuropeptide PrP106-126 aggregation by hexacoordinated ruthenium complexes.

Effects of Ruthenium Complexes on Prion Amyloid Peptide PrP115-135 Aggregation and Their Interaction Mechanism

Gold Complexes Inhibit the Aggregation of Prion Neuropeptides

The polyphenolic phytoalexin polydatin inhibits amyloid aggregation of recombinant human prion protein

Discovery of small molecules binding to the normal conformation of prion by combining virtual screening and multiple biological activity evaluation methods

Experimental and Theoretical Insights into the Inhibition Mechanism of Prion Fibrillation by Resveratrol and Its Derivatives

Effects of the Pathogenic Mutation A117V and the Protective Mutation H111S on the Folding and Aggregation of PrP106-126: Insights from Replica Exchange Molecular Dynamics Simulations.

Interaction of the Human Prion Protein Prp106-126 with Metal Complexes: Potential Therapeutic Agents Against Prion Disease

Protein misfolding cyclic amplification induces the conversion of recombinant prion protein to PrP oligomers causing neuronal apoptosis.

Interaction Between 14-3-3β and PrP Influences the Dimerization of 14-3-3 and Fibrillization of PrP106-126.

Antiamyloidogenic Chemical/Biochemical-Based Designed Nanoparticle as Artificial Chaperone for Efficient Inhibition of Protein Aggregation

Screening of Anti-Prion Compounds Using the Protein Misfolding Cyclic Amplification Technology

Inhibition of Prion Amyloid Peptide Fibril Formation by Peroxovanadium Complexes

Aminoquinolones and Their Benzoquinone Dimer Hybrids as Modulators of Prion Protein Conversion

Characterizing antiprion compounds based on their binding properties to prion proteins: Implications as medical chaperones

A simple in vitro assay for assessing the efficacy, mechanisms and kinetics of anti-prion fibril compounds